Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
115 shown of 9,605 total abstracts
  1. Abstract 68762026-04-02 · 14:30 CT · E450
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-299
    S. Modi, M.C. Garassino, R. Herbst, et al. · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract 69242026-04-03 · 18:15 CT · E450
    Quality of life outcomes with Keytruda in patients with RCC
    H. Borghaei, M. Reck, J. Cortes, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract 60282026-04-01 · 13:00 CT · Arie Crown Theater
    CheckMate-254: Opdivo (nivolumab) adjuvant in RCC
    M. Reck, M.C. Garassino, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  4. Abstract 61472026-04-04 · 21:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-313
    S. Antonia, S. Tolaney, J. Brahmer · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 60852026-04-02 · 20:45 CT · E450
    Quality of life outcomes with Opdivo in patients with RCC
    R. Herbst, J. Brahmer, S. Modi, et al. · National Cancer Center Japan
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  6. Abstract 61762026-04-02 · 20:45 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in RCC
    J. Cortes, J. Brahmer, S. Tolaney · Institut Gustave Roussy
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  7. Abstract 64272026-04-05 · 14:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-184 study)
    F. Andre, N. Rizvi, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract 63782026-04-04 · 21:15 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in RCC
    C. Robert, H. Borghaei, M. Krop, et al. · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  9. Abstract 66172026-04-02 · 21:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-128
    S. Modi, C. Saura · Dana-Farber Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  10. Abstract 61832026-04-05 · 21:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-948
    M. Krop, L. Paz-Ares, M. Reck · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  11. Abstract 63152026-04-02 · 19:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-732
    J. Cortes, N. Rizvi, L. Paz-Ares, et al. · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  12. Abstract 60512026-04-02 · 13:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-744 study)
    M.C. Garassino, S. Antonia · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 63772026-04-01 · 14:15 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-681
    A. Spira, C. Saura, S. Modi · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  14. Abstract LBA4013LBA2026-04-02 · 21:45 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-98
    F. Andre, C. Saura, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  15. Abstract 64082026-04-01 · 18:00 CT · S406
    Long-term follow-up of Opdivo 3L+ for RCC: CheckMate-201
    F. Andre, M. Krop, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  16. Abstract 62612026-04-04 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for RCC: KEYNOTE-702
    M. Reck, C. Robert, R. Herbst · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  17. Abstract 65712026-04-04 · 21:15 CT · Arie Crown Theater
    CheckMate-416: Opdivo (nivolumab) maintenance in RCC
    P. Schmid, T. Mok, L. Paz-Ares, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  18. Abstract 62592026-04-01 · 18:45 CT · Hall B1
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-605
    E. Winer, M. Krop, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  19. Abstract TPS80182026-04-01 · 21:15 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-232
    L. Paz-Ares, S. Modi, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  20. Abstract 65752026-04-02 · 18:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-361
    S. Peters, J. Brahmer, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  21. Abstract TPS80202026-04-04 · 13:15 CT · Arie Crown Theater
    KEYNOTE-643: Keytruda (pembrolizumab) adjuvant in RCC
    H. Borghaei, P. Schmid, F. Andre, et al. · Chinese University of Hong Kong
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  22. Abstract 61692026-04-01 · 15:45 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-615
    F. Andre, S. Peters, R. Herbst · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  23. Abstract 66402026-04-03 · 14:15 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-879
    M.C. Garassino, R. Herbst · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  24. Abstract LBA4023LBA2026-04-04 · 19:30 CT · E450
    KEYNOTE-504: Keytruda (pembrolizumab) adjuvant in RCC
    L. Paz-Ares, F. Andre, J. Brahmer, et al. · Cleveland Clinic
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  25. Abstract 63642026-04-05 · 19:45 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-567
    S. Peters, C. Saura, C. Robert · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  26. Abstract TPS80252026-04-05 · 13:00 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-762 study)
    S. Peters, G. Curigliano, F. Andre · Dana-Farber Cancer Institute
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  27. Abstract TPS80262026-04-02 · 19:00 CT · S406
    CheckMate-14: Opdivo (nivolumab) neoadjuvant in RCC
    T. Mok, R. Herbst, J. Brahmer, et al. · Massachusetts General Hospital
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  28. Abstract 62002026-04-01 · 18:00 CT · Hall B1
    CheckMate-253: Opdivo (nivolumab) 1L in RCC
    J. Brahmer, E. Winer · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  29. Abstract 61912026-04-02 · 20:15 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-166
    A. Spira, H. Rugo, C. Robert, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  30. Abstract e120292026-04-05 · 14:00 CT · Hall B1
    Long-term follow-up of Keytruda adjuvant for RCC: KEYNOTE-141
    T. Mok, S. Antonia, F. Andre · Karolinska Institute
    Publication OnlyGenitourinary Cancer—Kidney/Bladder📄🖼️
  31. Abstract 63912026-04-03 · 21:30 CT · S100A
    CheckMate-296: Opdivo (nivolumab) adjuvant in RCC
    C. Robert, P. Schmid, L. Paz-Ares, et al. · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  32. Abstract 62572026-04-03 · 15:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-977 study)
    H. Borghaei, S. Antonia · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  33. Abstract 67252026-04-02 · 20:00 CT · E450
    CheckMate-42: Opdivo (nivolumab) maintenance in RCC
    M. Reck, M.C. Garassino, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  34. Abstract 61082026-04-04 · 14:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-427 study)
    M.C. Garassino, S. Peters, S. Modi · Cleveland Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  35. Abstract 64752026-04-02 · 19:15 CT · S100A
    CheckMate-448: Opdivo (nivolumab) maintenance in RCC
    F. Andre, J. Brahmer, S. Modi, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  36. Abstract 63732026-04-05 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-608 study)
    A. Spira, M. Krop, S. Modi, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  37. Abstract 64032026-04-04 · 19:30 CT · Hall B1
    KEYNOTE-242: Keytruda (pembrolizumab) 1L in RCC
    M.C. Garassino, M. Krop, R. Herbst, et al. · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  38. Abstract e120372026-04-03 · 20:15 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-65
    C. Saura, M. Reck, H. Rugo · Chinese University of Hong Kong
    Publication OnlyGenitourinary Cancer—Kidney/Bladder📄🖼️
  39. Abstract 62212026-04-05 · 16:00 CT · Arie Crown Theater
    CheckMate-198: Opdivo (nivolumab) 3L+ in RCC
    G. Curigliano, J. Brahmer, S. Antonia, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  40. Abstract 69072026-04-02 · 13:00 CT · E450
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-677
    C. Saura, S. Peters · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  41. Abstract 65952026-04-03 · 16:45 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-511 study)
    T. Mok, C. Robert, E. Winer, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  42. Abstract 62252026-04-05 · 14:15 CT · S100A
    CheckMate-955: Opdivo (nivolumab) adjuvant in RCC
    T. Mok, J. Brahmer · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  43. Abstract 61292026-04-03 · 18:30 CT · Arie Crown Theater
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-573
    E. Winer, C. Robert, T. Mok, et al. · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  44. Abstract LBA4043LBA2026-04-05 · 13:45 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-898 study)
    P. Schmid, G. Curigliano · Massachusetts General Hospital
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  45. Abstract 63262026-04-05 · 20:15 CT · S406
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-639
    G. Curigliano, H. Rugo, J. Cortes · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  46. Abstract 68552026-04-03 · 13:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-855 study)
    L. Paz-Ares, S. Peters, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  47. Abstract 61942026-04-02 · 16:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-592
    S. Peters, A. Spira, R. Herbst, et al. · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  48. Abstract 61072026-04-02 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-882
    S. Antonia, L. Paz-Ares, M. Reck, et al. · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  49. Abstract 62182026-04-04 · 14:45 CT · Hall B1
    Long-term follow-up of Opdivo 3L+ for RCC: CheckMate-600
    J. Cortes, S. Modi · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  50. Abstract 68942026-04-01 · 18:30 CT · Arie Crown Theater
    CheckMate-382: Opdivo (nivolumab) neoadjuvant in RCC
    J. Cortes, M. Krop, S. Tolaney, et al. · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  51. Abstract 62572026-04-05 · 16:00 CT · E450
    CheckMate-690: Opdivo (nivolumab) neoadjuvant in RCC
    C. Robert, J. Brahmer · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  52. Abstract 63762026-04-03 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-658 study)
    S. Modi, S. Antonia, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  53. Abstract 64752026-04-03 · 21:30 CT · E450
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-298
    J. Brahmer, S. Modi, A. Spira, et al. · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  54. Abstract 62012026-04-05 · 16:00 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-180 study)
    H. Rugo, T. Mok, S. Modi, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  55. Abstract 66192026-04-03 · 18:30 CT · Hall B1
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-57
    H. Borghaei, S. Antonia, P. Schmid, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  56. Abstract 62012026-04-05 · 18:45 CT · S406
    CheckMate-623: Opdivo (nivolumab) 3L+ in RCC
    M.C. Garassino, A. Spira, P. Schmid, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  57. Abstract 68422026-04-03 · 21:15 CT · S406
    CheckMate-708: Opdivo (nivolumab) 3L+ in RCC
    J. Brahmer, M. Krop · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  58. Abstract 69442026-04-03 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-513
    L. Paz-Ares, E. Winer, S. Antonia · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  59. Abstract 65912026-04-05 · 13:30 CT · Arie Crown Theater
    CheckMate-746: Opdivo (nivolumab) 1L in RCC
    S. Peters, T. Mok · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  60. Abstract 69552026-04-04 · 14:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-915
    H. Borghaei, R. Herbst, C. Robert, et al. · Cleveland Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  61. Abstract 69142026-04-01 · 21:45 CT · Hall B1
    KEYNOTE-197: Keytruda (pembrolizumab) 1L in RCC
    H. Rugo, C. Robert, J. Cortes, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  62. Abstract TPS80612026-04-04 · 15:15 CT · E450
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-660
    S. Modi, F. Andre · Peter MacCallum Cancer Centre
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  63. Abstract 66632026-04-05 · 21:00 CT · S100A
    CheckMate-538: Opdivo (nivolumab) 1L in RCC
    C. Robert, M. Krop · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  64. Abstract 64232026-04-03 · 15:30 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-539 study)
    C. Saura, E. Winer, S. Tolaney · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  65. Abstract 69472026-04-01 · 18:30 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 3L+ for RCC: CheckMate-928
    L. Paz-Ares, M. Reck · Karolinska Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  66. Abstract 62972026-04-02 · 14:30 CT · E450
    KEYNOTE-65: Keytruda (pembrolizumab) adjuvant in RCC
    S. Peters, H. Rugo, C. Robert · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  67. Abstract 60522026-04-03 · 18:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-556 study)
    G. Curigliano, M. Reck, R. Herbst, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  68. Abstract 64332026-04-02 · 20:15 CT · S406
    CheckMate-507: Opdivo (nivolumab) maintenance in RCC
    C. Robert, M. Reck, H. Rugo · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  69. Abstract 66732026-04-04 · 18:15 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-633 study)
    A. Spira, H. Borghaei · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  70. Abstract e120692026-04-05 · 16:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-252
    J. Brahmer, P. Schmid, S. Tolaney · Princess Margaret Cancer Centre
    Publication OnlyGenitourinary Cancer—Kidney/Bladder📄🖼️
  71. Abstract 60922026-04-02 · 15:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-772
    C. Saura, M. Reck, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  72. Abstract 69782026-04-04 · 16:15 CT · E450
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-349
    S. Tolaney, F. Andre, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  73. Abstract 63392026-04-05 · 18:15 CT · S100A
    CheckMate-170: Opdivo (nivolumab) adjuvant in RCC
    A. Spira, M.C. Garassino, S. Tolaney, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  74. Abstract 61352026-04-03 · 15:15 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-175
    S. Antonia, J. Brahmer, G. Curigliano, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  75. Abstract 62762026-04-03 · 16:30 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-605
    S. Peters, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  76. Abstract 64472026-04-02 · 21:45 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-424
    H. Borghaei, J. Cortes, S. Antonia, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  77. Abstract 67612026-04-03 · 14:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-322
    P. Schmid, H. Borghaei, M. Reck · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  78. Abstract 61622026-04-04 · 19:30 CT · S406
    KEYNOTE-128: Keytruda (pembrolizumab) 1L in RCC
    H. Rugo, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  79. Abstract 61562026-04-05 · 14:45 CT · S100A
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-177
    R. Herbst, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  80. Abstract 61062026-04-01 · 15:15 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-411
    M. Krop, P. Schmid, F. Andre, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  81. Abstract 68612026-04-02 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-456 study)
    C. Robert, C. Saura, J. Cortes, et al. · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  82. Abstract 60142026-04-05 · 20:00 CT · S406
    KEYNOTE-539: Keytruda (pembrolizumab) 1L in RCC
    N. Rizvi, M. Reck, E. Winer, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  83. Abstract 67362026-04-03 · 21:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-156
    R. Herbst, F. Andre · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  84. Abstract 62402026-04-05 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-327 study)
    S. Peters, M. Krop · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  85. Abstract 64122026-04-01 · 13:45 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-142 study)
    C. Robert, T. Mok, H. Borghaei, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  86. Abstract 67852026-04-01 · 21:30 CT · Hall B1
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-226
    M. Krop, S. Modi, G. Curigliano, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  87. Abstract 60162026-04-04 · 18:45 CT · S100A
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-971
    E. Winer, J. Cortes, M. Reck · MD Anderson Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  88. Abstract 65462026-04-04 · 19:15 CT · S100A
    CheckMate-722: Opdivo (nivolumab) adjuvant in RCC
    G. Curigliano, J. Cortes, J. Brahmer, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  89. Abstract 60092026-04-01 · 13:00 CT · S406
    CheckMate-556: Opdivo (nivolumab) 3L+ in RCC
    S. Antonia, A. Spira · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  90. Abstract 60582026-04-03 · 15:00 CT · S406
    KEYNOTE-757: Keytruda (pembrolizumab) adjuvant in RCC
    S. Antonia, P. Schmid, F. Andre · Mayo Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  91. Abstract 61212026-04-01 · 13:45 CT · E450
    CheckMate-152: Opdivo (nivolumab) adjuvant in RCC
    C. Robert, S. Peters · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  92. Abstract 60452026-04-03 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-230 study)
    M.C. Garassino, M. Reck, F. Andre · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  93. Abstract 63832026-04-02 · 18:45 CT · E450
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-848
    S. Modi, A. Spira, H. Rugo, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  94. Abstract 60862026-04-02 · 16:30 CT · S406
    CheckMate-760: Opdivo (nivolumab) 1L in RCC
    C. Saura, N. Rizvi, H. Rugo · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  95. Abstract 61462026-04-03 · 19:15 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for RCC: KEYNOTE-374
    T. Mok, H. Borghaei, C. Saura, et al. · Mayo Clinic
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  96. Abstract 66612026-04-01 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-508 study)
    S. Peters, S. Tolaney, C. Robert · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  97. Abstract 62262026-04-05 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-112 study)
    C. Saura, S. Peters, E. Winer · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  98. Abstract LBA4097LBA2026-04-01 · 14:45 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-887 study)
    F. Andre, C. Robert · Stanford Cancer Institute
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  99. Abstract 68482026-04-02 · 20:45 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-952
    S. Peters, F. Andre · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  100. Abstract 63462026-04-02 · 18:30 CT · E450
    KEYNOTE-404: Keytruda (pembrolizumab) adjuvant in RCC
    S. Tolaney, F. Andre, R. Herbst, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  101. Abstract 61542026-04-05 · 19:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-894 study)
    E. Winer, J. Cortes, S. Antonia, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  102. Abstract 67482026-04-04 · 16:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-359
    G. Curigliano, H. Rugo, P. Schmid, et al. · University of Chicago
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  103. Abstract 64212026-04-01 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-30
    S. Tolaney, J. Cortes, S. Modi, et al. · National Cancer Center Japan
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  104. Abstract 60712026-04-01 · 14:45 CT · Hall B1
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-276
    C. Saura, J. Brahmer, S. Peters, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  105. Abstract 63582026-04-01 · 16:45 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-780
    A. Spira, T. Mok, M. Krop · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  106. Abstract 69402026-04-03 · 15:15 CT · S100A
    KEYNOTE-662: Keytruda (pembrolizumab) adjuvant in RCC
    N. Rizvi, R. Herbst, H. Borghaei · Stanford Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  107. Abstract 67592026-04-05 · 13:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-138
    J. Cortes, S. Peters · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  108. Abstract 62332026-04-01 · 18:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-907
    T. Mok, G. Curigliano, P. Schmid · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  109. Abstract 65442026-04-04 · 14:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-133
    J. Brahmer, M.C. Garassino · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  110. Abstract e121092026-04-01 · 16:00 CT · Arie Crown Theater
    KEYNOTE-280: Keytruda (pembrolizumab) maintenance in RCC
    S. Modi, S. Tolaney, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Publication OnlyGenitourinary Cancer—Kidney/Bladder📄🖼️
  111. Abstract 61942026-04-03 · 14:45 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-900 study)
    M.C. Garassino, S. Modi, M. Krop, et al. · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  112. Abstract 67852026-04-02 · 13:15 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-945
    L. Paz-Ares, H. Rugo, S. Antonia, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  113. Abstract 69602026-04-05 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-192 study)
    S. Peters, H. Rugo, C. Robert, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  114. Abstract 62072026-04-05 · 19:00 CT · Hall B1
    KEYNOTE-436: Keytruda (pembrolizumab) 2L in RCC
    M. Reck, A. Spira, C. Robert, et al. · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  115. Abstract 64882026-04-01 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda adjuvant for RCC: KEYNOTE-156
    M. Reck, M.C. Garassino, S. Modi · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.